NHI.no
Annonse
Informasjon

Diabetes type 2

Diabetes type 2 er en kronisk sykdom som kjennetegnes ved mangel på hormonet insulin eller dårlig virkning av insulin. Den viktigste årsaken til type 2 diabetes er overvekt og usunn livsstil, men også arv kan spille en rolle.

Diabetes type 2

Sist oppdatert:

8. jan. 2020

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Diabetes type 2 . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonale faglig retningslinje for diabetes. Oslo; Helsedirektoratet 2016. Sist oppdatert 16.03.2021. Siden lest 06.05.2021. helsedirektoratet.no
  2. Stene LC, Ruiz PL-D, Åsvold BO, et al. Hvor mange har diabetes i Norge i 2020?. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0849 DOI
  3. Berge T. Lyngbakken MN, Smith P, et al. High prevalence of known and unknown type 2 diabetes mellitus among middle-aged Norwegians: Data from the Akershus cardiac examination (ACE) 1950 study. Poster ESC congress 2018. esc365.escardio.org
  4. Ruiz PLD, Stene LC, Bakken IJ, et al. Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study. Diabetologia 2018. pmid:29995214 PubMed
  5. IDF Diabetes Atlas. International Diabetes Federation. Diabetes around the world in 2021. diabetesatlas.org
  6. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015; 314: 1021-9. doi: 10.1001/jama.2015.10029. DOI
  7. Lahti-Pulkkinen M, Bhattacharya S, Wild SH et al. Consequences of being overweight or obese during pregnancy on diabetes in the offspring: a record linkage study in Aberdeen, Scotland. Diabetologica 2019. pmid:31214738 PubMed
  8. Jayedi A, Soltani S, Motlagh SZ, et al. CCBYNC Open access Research Anthropometric and adiposity indicators and risk of type 2 diabetes: systematic review and dose-response meta-analysis of cohort studies. BMJ 2022; 376: e067516. doi:10.1136/bmj-2021-067516 DOI
  9. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 2000; 132: 501-13. PubMed
  10. Folkehelseinstituttet. Overvekt og fedme. Folkehelserapporten 2017. Sist oppdatert 04.10.2017. Siden besøkt 20.02.2018 www.fhi.no
  11. NICE Guidance. Obesity: identification, assessment and management. Last updated 08 September 2022. www.nice.org.uk
  12. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015 Jul;19(57):1-210. PubMed
  13. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: A patient-centered approach. Diabetes Care 2012; 35: 1364-79. doi: 10.2337/dc12-0413 DOI
  14. Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017 Jun 8;6:CD010137. doi: 10.1002/14651858.CD010137.pub2. (Review) PMID: 28594069 PubMed
  15. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. New England Journal of Medicine
  16. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2017. pmid:29221645 PubMed
  17. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2021. pmid:34600604 PubMed
  18. Lee SF, Pei D, Chi MJ, et al. An investigation and comparison of the effectiveness of different exercise programmes in improving glucose metabolism and pancreatic beta cell function of type 2 diabetes patients. Int J Clin Pract. 2015. PMID: 26119968 PubMed
  19. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen P. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93. PubMed
  20. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy fortype 2 diabetes. Ann Intern Med 2016. doi:10.7326/M15-2650 DOI
  21. Renders CM, Valk GD, Griffin SJ, Wagner E, van Eijk JT, Assendelft WJJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD001481. DOI: 10.1002/14651858.CD001481 DOI
  22. Zhu J, Yu X, Zheng Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol. 2020 Mar;8(3):192-205. PMID: 32006518 PubMed
  23. Nield L, Moore H, Hooper L, Cruickshank K, Vyas A, Whittaker V, Summerbell CD. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004097. DOI: 10.1002/14651858.CD004097.pub4. DOI
  24. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575 PubMed
  25. Jenkins DJA, Kendall CWC, McKeown-Eyssen G, et al. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes. JAMA 2008; 300: 2742-53. PubMed
  26. Reynolds AN, Akerman AP, Mann J Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses. PLoS Med. 2020 Mar 6;17(3):e1003053. PMID: 32142510 PubMed
  27. Hodson EM, Cooper TE Altered dietary salt intake for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2023 Jan 16;1(1):CD006763. PMID: 36645291 PubMed
  28. Coppell K, Kataoka M, Williams SM, et al. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ 2010; 341: c3337. BMJ (DOI)
  29. Jiao J, Liu G, Shin HJ, et al. Dietary fats and mortality among patients with type 2 diabetes: analysis in two population based cohort studies. BMJ 2019; 366: l4009. pmid:31266749 PubMed
  30. Ochoa-Rosales. Daily cup of coffee cuts type 2 diabetes risk by about 5%. UK Biobank stury and Rotterdam study. Cardiology News at Epidemiology and Prevention/Lifestyle & Cardiometabolic Health meeting 2021. www.mdedge.com
  31. Ma L, Hu Y, Alperet DJ, et al. CCBY Open access Research Beverage consumption and mortality among adults with type 2 diabetes: prospective cohort study. BMJ 2023; 381: e073406. pmid:37076174 PubMed
  32. Dahl-Petersen I, Eriksen L, Haugaard SB, Dela F. Fysisk træning ved type 2-diabetes. Ugeskr Læger 2009; 171: 878. Ugeskrift for Læger
  33. Avery L, Flynn D, van Wersch A, et al. Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions. Diabetes Care 2012; 35: 2681-9. PubMed
  34. Heberle I, de Barcelos GT, Silveira LMP, et al. Effects of aerobic training with and without progression on blood pressure in patients with type 2 diabetes: A systematic review with meta-analyses and meta-regressions. Diabetes Res Clin Pract. 2021 Jan;171:108581. PMID: 33307131 PubMed
  35. Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet 2023. doi:10.1016/S0140-6736(23)01127-3 DOI
  36. Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: A clinical practice guideline. BMJ 2021 May 11; 373:n1091. PMID: 33975892 PubMed
  37. Xu T, Brandmaier S, Messias AC, et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Dia Care 2015. doi:10.2337/dc15-0658 DOI
  38. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497. British Medical Journal
  39. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2012 Dec 10. pmid:23230096 PubMed
  40. Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8:e71583. doi: 10.1371/journal.pone.0071583 DOI
  41. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340: c2181. BMJ (DOI)
  42. Wile DJ, Toth C. Association of metformin, elevated homocysteine, amd methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010; 33: 156-61. PubMed
  43. Holst H, Eldrup E, Guldstad NH, et al. Laktatacidose ved behandling af type 2-diabetes med metformin. Ugeskr Læger 2012; 174: 1598. Ugeskrift for Læger
  44. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD002967. DOI: 10.1002/14651858.CD002967.pub4. DOI
  45. Lazarus B, Wu A, Shin J-I, et al. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Intern Med 2018; 178: 903-10. pmid:29868840 PubMed
  46. Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312: 2668-75. doi:10.1001/jama.2014.15298 DOI
  47. Orloff J, Min JY, Mushlin A, et al. Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. Diabetes Obes Metab. 2021. PMiD: 34009711 PubMed
  48. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 252-61. PubMed
  49. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: a systematic review and meta-analysis. BMJ 2012; 344: e1369. BMJ (DOI)
  50. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014; 15: 348 :g2366. doi: 10.1136/bmj.g2366. DOI
  51. EMA: Investigation into GLP-1 based diabetes therapies concluded, 2013-07-26 http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/07/WC500146619.pdf
  52. Lee M, Sun J, Han M, et al. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care 2019; 42: 2057-64. pmid:31431452 PubMed
  53. He L, Wang J, Ping F, et al. CCBYNC Open access Research Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ 2022. pmid:35764326 PubMed
  54. Green JB, Betehel MA, Armsrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015. doi: 10.1056/NEJMoa1501352 DOI
  55. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013. doi: 10.1056/NEJMoa1307684 DOI
  56. Faillie JL, Filion KB, Patenaude V, et al. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 379-85. doi:10.1111/dom.12431 DOI
  57. Engel SS, Round E, Golm GT, et al. . Safety and tolerability of sitagliptin in type 2 diabetes: Pooled analysis of 25 clinical studies. Diabetes Ther 2013; 4: 119-45. doi: 10.1007/s13300-013-0024-0 DOI
  58. FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. FDA Drug Safety Communication, aug. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm
  59. Abrahami D, Douros A,Yin H, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: Population based cohort study. BMJ 2018; 360: k872. pmid:29563098 PubMed
  60. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA 2018; 319: 1580-91. pmid:29677303 PubMed
  61. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013. PMID: 24320621 PubMed
  62. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ 2021 Jan 13; 372:m4573. PMID: 33441402 PubMed
  63. Shi Q, Nong K, Vandvik PO, Guyatt G, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023; 381: e074068. pmid:37024129 PubMed
  64. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2013. doi:10.1111/dom.12239 DOI
  65. Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014 ;30(3):204-21. doi: 10.1002/dmrr.2479.
  66. Rosenstock J, Chuck L, Gonzalez-Ortiz M, et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes. Diabetes Care 2016. PMID: 26786577 PubMed
  67. Escobar C, Barrios V, Cosin J, et al. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Diabet Med 2021; 38: e14502. PMID: 33368612 PubMed
  68. Kosiborod M, Lam CSP, Kohsaka S, et al. Lower cardiovascular risk associated with SGLT-2 in >400,000 patients: The CVD-REAL 2 study. J Am Coll Cardiol 2018 Mar 11; e-pub. PMID: 29540325 PubMed
  69. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015. doi:10.1056/NEJMoa1504720 DOI
  70. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2018. doi:10.1016/S0140-6736(18)32590-X DOI
  71. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016. PMID: 26819227 PubMed
  72. Kosiborod M, Cavender MA, Fu AZ, et al.. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study. Circulation 2017; CIRCULATIONAHA: 117.029190. pmid:28522450 PubMed
  73. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2017. pmid:29133604 PubMed
  74. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019. pmid:31535829 PubMed
  75. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020. pmid:32966714 PubMed
  76. Perkovic V, Jardine MJ, Neal B, et al. (CREDENCE Trial Investigators). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019. PMID: 30990260 PubMed
  77. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. PMID: 31495651 PubMed
  78. Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med. 2019 Dec 9;16(12):e1002983. PMID: 31815931 PubMed
  79. Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: Synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med 2023. PMID: 36623286 PubMed
  80. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018; 363: k4365. pmid:30429124 PubMed
  81. Dave CV, Schneeweiss S, Kim D, et al. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med 2019. pmid:31357213 PubMed
  82. Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med 2019. pmid:31060053 PubMed
  83. Abrahami D, Tesfaye H, Yin H, et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. 2022. PMID: 36170656 PubMed
  84. Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014; 31: 176-84. PMID: 24117597 PubMed
  85. D'Alessio, D., Häring, H.-U., Charbonnel, B, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes, Obesity and Metabolism 2015; 17: 170-8. doi:10.1111/dom.12406 DOI
  86. Eng C, Kramer CK, Zinman B, Retnakaran R. Glukagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014. doi:10.1016/S0140-6736(14)61335-0 DOI
  87. Yuan D, Sharma H, Krishnan A, et al. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.. Diabetes Obes Metab 2022. pmid:35589615 PubMed
  88. Strain WD, Frenkel O, James MA, et al. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke 2022. pmid:35582947 PubMed
  89. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311-22. PMID: 27295427 PubMed
  90. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-48. pmid:28854085 PubMed
  91. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial. JAMA 2019. doi:10.1001/jama.2019.2942 DOI
  92. Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-labeled randomised trial. Lancet 2010; 375: 2234-43. PubMed
  93. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.. Lancet Diabetes Endocrinol 2018; 6: 105-13. pmid:29221659 PubMed
  94. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. pmid: 31422062 PubMed
  95. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021. PMID: 34672967 PubMed
  96. Lingvay I, Capehorn MS, Catarig A-M, et al. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. J Clin Endocrinol Metab 2020. pmid:32827435 PubMed
  97. Lund SS, Tarnow L, Frandsen M, et al. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009; 339: b4324. BMJ (DOI)
  98. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. PubMed
  99. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65. PubMed
  100. Birkeland KI. Insulinbehandling ved type 2-diabetes. Tidsskr Nor Lægeforen 2006; 126: 919-20. PubMed
  101. Holman RR, Farmer AJ, Davies MJ, et al. Threee-year efficacy om complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-47. New England Journal of Medicine
  102. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016; 352: i717. doi:10.1136/bmj.i717 DOI
  103. Birkeland KI, Claudi T, Hansteen V, Hanssen KF, Hjermann I, Jenssen T, Jervell J, Os I. Forebygging av hjerte- og karsykdom ved type 2-diabetes. Tidsskr Nor Lægeforen 2000; 120: 2554-9. PubMed
  104. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-76. New England Journal of Medicine
  105. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD008277. DOI: 10.1002/14651858.CD008277.pub2. Accessed 16 November 2021. The Cochrane Library
  106. McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012 Aug 6:1-8 . pmid:PMID: 22868819 PubMed
  107. The ACCORD study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; : 10.1056/NEJMoa1001286.
  108. Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14:148. doi: 10.1186/1471-2261-14-148 DOI
  109. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-81. doi: 10.1016/S0140-6736(10)61350-5 DOI
  110. Mansi IA, Chansard M, Lingvay I, et al. Association of Statin Therapy Initiation With Diabetes Progression A Retrospective Matched-Cohort Study. JAMA Intern Med 2021. pmid:34605849 PubMed
  111. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-84. doi:10.1056/NEJMoa1211585 DOI
  112. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Syst Rev 2014; 4:CD007938. DOI: 10.1002/14651858.CD007938.pub3 DOI
  113. Bril V, England J, Franklin GM, et al. Evience-based guideline: Treatment of painful diabethic neuropathy. Neurology 2011; 76: 1. Neurology
  114. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013 ;11:CD010567. doi: 10.1002/14651858.CD010567.pub2 DOI
  115. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2021. pmid:33485454 PubMed
  116. Hofsø D, Fatima F, Borgeraas H, Birkeland KI, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7: 912-924. pmid:31678062 PubMed
  117. Doumouras AG, Lee Y, Paterson M, et al. Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. JAMA Netw Open 2021. doi:10.1001/jamanetworkopen.2021.6820 DOI
  118. Barry E, Roberts S, Oke J, et al. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 2017; 356: i6538. pmid:28052845 PubMed
  119. Balk EM, Earley A, Raman G et al. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med 2015; 163(6): 437-51. pmid:26167912 PubMed
  120. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. . Lancet 2012 Oct 3. pmid:23040422 PubMed
  121. Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: Risk based analysis of Diabetes Prevention Program. BMJ 2015; 350:h454 BMJ (DOI)
  122. Jayedi A, Zargar M-S, Emadi A, Aune D. Walking speed and the risk of type 2 diabetes: a systematic review and meta-analysis. BMJ Sport Med 2023. doi:10.1136/bjsports-2023-107336 DOI
  123. Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in swedish obese subjects. N Engl J Med 2012; 367: 695-704. New England Journal of Medicine
  124. Martínez-González MA, Fuente-Arrillaga C, Nunez-Cordoba JM et al. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study . BMJ 2008; 336: 1348-51. PubMed
  125. Koloverou E, Esposito K, Giugliano D, et al. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants. Metabolism. 2014 ;63(7):903-11. doi: 10.1016/j.metabol.2014.04.010 DOI
  126. Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects - The Carmos Study. Exp Clin Endocrinol Diabetes 2009. PMID: 19053032 PubMed
  127. Lee CG, Heckman-Stoddard B, Dabelea D, et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2021; 44: 2775-82. pmid:34697033 PubMed
  128. Abuissa H, Jones PG, Marso SP, O'keefe JH Jr. Angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers for prevention of type 2 diabetes a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-6. PubMed
  129. Hemmingsen B, Sonne DP, Metzendorf MI, et al. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2016; 10: CD012151. pmid:27749986 PubMed
  130. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017. pmid:28237263 PubMed
  131. Pittas AG, Kawahara T, Jorde R, et al. Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Ann Intern Med. 2023. PMID: 36745886 PubMed
  132. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. New England Journal of Medicine
  133. Anderson RT, Narayan KM, Feeney P, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care 2011; 34: 807-12. PubMed
  134. Ivy JL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Med 1997; 24: 321 - 36. PubMed
  135. Deakin TA, McShane CE, Cade JE, Williams R. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003417. DOI: 10.1002/14651858.CD003417.pub2. DOI
  136. Bjørgaas M. Hypoglykemi - en fryktet komplikasjon ved diabetes. Tidsskr Nor Lægeforen 2000; 120: 2441-4. Tidsskrift for Den norske legeforening
  137. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36: 376-82. PubMed
  138. Nyirenda MJ, Sandeep T, Grant I et al. Severe acidosis in patients taking metformin - rapid reversal and survival despite high APACHE score. Diabet Med 2006; 23: 432-5. PubMed
  139. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373:1720-1732 . doi:10.1056/NEJMoa1504347 DOI
  140. Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2018; 379: 633-44. pmid:30110583 PubMed
  141. Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration.. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018; 6: 538-46. pmid:29752194 PubMed
  142. Gyldenkerne C, Mortensen MB, Kahlert J, et al. 10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus. J Am Coll Cardiol 2023; 82: 1583-1594. pmid:37821168 PubMed
  143. Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol 2023. pmid:37708900 PubMed
  144. Tancredi M, Rosengren A, Svensson A-M, et al. Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Openheart 2019. doi:10.1136/openhrt-2018-000967 DOI
  145. Young LA, Buse JB, Weaver MA, et al.. Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. JAMA Intern Med 2017. pmid:28600913 PubMed
  146. Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved ulike kliniske problemstillinger. Siden besøkt 19.11.2020. www.noklus.no
  147. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023. doi:10.1093/eurheartj/ehad192 DOI
Annonse
Annonse